For example, although higher objective response and disease control rates, along with elevated frequencies of cytolytic tumor antigen-specific T cells, were seen in patients with metastatic colorectal carcinoma receiving polychemotherapy with gemcitabine plus oxaliplatin, fluorouracil, and folinic acid (FOLFOX-4) followed by granulocyte-macrophage colony-stimulating factor (GM-CSF) and low-dose interleukin-2 (IL-2) [1], addition of IL-2 and interferon-alpha2b did not increase the efficacy of cisplatin, vindesine and dacarbazine in melanoma patients [2]. Here, CSF2 is linked to melanoma.